Skip to main
VKTX

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics is a clinical-stage biotechnology company developing therapies for metabolic and endocrine disorders. They have a lead asset, VK2735, which has shown positive results in Phase 2 trials for obesity and has potential for cardiometabolic benefits beyond weight loss. Additionally, they have a diverse pipeline including VK2809 for non-alcoholic steatohepatitis (NASH) and VK0214 for X-linked adrenoleukodystrophy (X-ALD), positioning the company for potential growth and partnership opportunities. Management has a solid plan in place for expanding access and driving adoption, and with a strong cash balance and positive updates on their clinical programs, Viking Therapeutics is well-positioned for future success in the biopharmaceutical industry.

Bears say

Viking Therapeutics is facing potential legal issues with regards to their license agreement for their lead compounds VK2809 and VK0214, causing uncertainty in the company's ability to develop and commercialize these products. Additionally, their titration schema and treatment period for clinical trials may not be as efficient and cost-effective as originally anticipated, leading to potential delays and increased expenses. Furthermore, there is a risk of unexpected delays or regulatory barriers in their clinical development, and despite having a strong cash runway, there is limited visibility on potential partnership opportunities, creating a negative outlook on the stock.

Viking Therapeutics (VKTX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 9 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $95.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $95.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.